<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/re.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
    

</head>

<body class="slide-2">

<div id="content">
<div class="collage"></div>

<header>
Resistance analysis in treatment-naïve patients

</header>

<div class="logo"></div>

<section>

<article>

    <div class="chartbk"></div>
    <div class="chartdisc">
    <p>* Viral rebound defined as HIV-1 RNA &gt;50 copies/mL confirmed with a second measurement of &gt;400 copies/mL within 4 weeks. LPV resistance was defined as the presence of 1 or more of the following protease mutations: I47V or A, G48V, I50V, V82A, or F, or T, or S, I84V, L90M; or the presence of 3 or more of the following protease mutations: L10F or I or R or V, K20M or R, L24I, V32I, L33F, M36I, M46I or L, F53L, any changes to I54, A71V or T, and G73S.<sup>2</sup> </p>
	<p><sup id="cross" class="symbol">†</sup>Detectable viral load defined as HIV RNA &gt;400 copies/mL. Resistance to lopinavir defined as: any primary or active-site mutation (8, 30, 32, 46, 47, 48, 50, 54, 82, 84, and 90) in HIV protease, confirmed by phenotype analysis.<sup>3</sup></p>
    
    
    </div>

</article>

<aside>

<p><strong>Safety Considerations</strong></p>
<p class="bullet">HIV cross-resistance among protease inhibitors has not been fully explored in KALETRA-treated patients; it is unknown what effect therapy with KALETRA will have on the activity of subsequently administered protease inhibitors.</p>
<p class="bullet">Various degrees of cross-resistance<br>have been observed among PIs. </p>
<p class="bullet">Resistance to KALETRA has<br>emerged in patients treated with<br>other PIs prior to KALETRA therapy.</p>

</aside>

</section>

<div class="buttonwrap">
    <button onclick="makecall('PopupWithHeader',Array('re-02-popup-02','730Study Design','<table width=\'680px\'><tr align=\'center\'><td class=\'reference\'>730 Study Design<sup>2</sup></td></tr></table>','90','618','10','0','680','545','1','0','1','0'));">730<br>Study Design</button>
    <button onclick="makecall('PopupWithHeader',Array('re-02-popup-01','720Study Design','<table width=\'970px\'><tr align=\'center\'><td class=\'reference\'>720 Study Design<sup>3,4</sup></td></tr></table>','230','618','10','0','970','450','1','0','1','0'));">720<br>Study Design</button>
</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>